UHS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Buy now. UHS is trading near key support (S1 197.5) with improving momentum (MACD turning up) and a relatively washed-out short-term RSI (38). Fundamentals from 2025/Q3 show strong growth, and while some 2026 caution is creeping into analyst commentary, Street price targets still imply meaningful upside from ~201. The lack of proprietary buy signals and elevated insider selling are real negatives, but the current technical setup near support + solid prior-quarter execution makes this a good immediate-entry buy for an impatient investor.
Price ~201.26 post-market sits below the pivot (204.09), indicating the stock is still working through a consolidation/soft patch, but it is close to support (S1 197.48; S2 193.39), which often creates a favorable buy point for a bounce. Momentum is improving: MACD histogram is positive (0.25) and expanding, suggesting the down-move is losing control and a reversal attempt is underway. RSI(6) at ~38 is weak-to-neutral (not overbought), consistent with a stock that has room to rebound. Moving averages are converging, typically preceding a larger directional move; a reclaim of 204–205 would be a near-term bullish confirmation, with resistances at ~210.7 and ~214.8.
Strong operating momentum shown in 2025/Q3 (double-digit revenue growth and strong EPS expansion), which can continue to support multiple expansion if execution holds.
Sector read-through: peer HCA posted higher earnings and announced a large buyback, reinforcing resilient hospital demand and shareholder-return appetite in the space.
Technical: proximity to support with a positive/expanding MACD raises the odds of a near-term rebound.
Insider selling has accelerated materially (selling amount up ~291% over the last month), which can cap near-term upside.
Analyst narrative has recently become more cautious on 2026 hospital/legislative backdrop (notably the Wells Fargo downgrade and lowered targets).
Options volume skew (put/call volume >
indicates traders are currently more defensive than bullish in the very short term.
No notable hedge fund accumulation trend (neutral).
Latest reported quarter: 2025/Q3. Revenue grew to ~$4.495B (+13.43% YoY). Net income rose to ~$373.0M (+44.16% YoY). EPS increased to $5.86 (+54.21% YoY). Overall, the quarter shows accelerating profitability and strong operating leverage (earnings growing much faster than revenue), which supports the bull case for buying on technical weakness near support.
Recent trend: After several bullish moves in early November (Raymond James upgrade to Outperform; Mizuho raised PT; Wells initially raised PT), January brought a more cautious reset: Wells Fargo downgraded to Equal Weight with a lower PT ($235), and TD Cowen/Barclays trimmed targets (to $245 and $262) while keeping Buy/Overweight. Net: Wall Street is still broadly constructive with price targets well above ~$201, but the marginal direction is slightly negative (targets drifting down) due to 2026 policy/payor-mix uncertainty. Pros: strong execution, demand resilience, attractive upside vs targets. Cons: 2026 policy/Exchange/ACA-subsidy risks, tougher hospital backdrop as post-COVID tailwinds fade, and increased insider selling.
